MBX Biosciences, Inc.
NMS: MBXLive Quote
📈 ZcoreAI Score
Our AI model analyzes MBX Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MBX Z-Score →About MBX Biosciences, Inc.
Healthcare
Biotechnology
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
📊 Fundamental Analysis
MBX Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -27.8%, which indicates that capital utilization is currently under pressure.
At a current price of $31.00, MBX currently sits at the 64th percentile of its 52-week range (Range: $6.81 - $44.89).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.47B
Trailing P/E
--
Forward P/E
-7.63
Beta (5Y)
--
52W High
$44.89
52W Low
$6.81
Avg Volume
617K
Day High
Day Low